bluebird bio Company Profile (NASDAQ:BLUE)

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLUE
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.27 billion
  • Outstanding Shares: 40,950,000
Average Prices:
  • 50 Day Moving Avg: $86.31
  • 200 Day Moving Avg: $76.75
  • 52 Week Range: $36.62 - $100.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.98
  • P/E Growth: 0.29
Sales & Book Value:
  • Annual Revenue: $11.49 million
  • Price / Sales: 284.40
  • Book Value: $19.92 per share
  • Price / Book: 4.01
  • EBIDTA: ($250,640,000.00)
  • Net Margins: -3,941.72%
  • Return on Equity: -30.79%
  • Return on Assets: -24.93%
  • Current Ratio: 9.01%
  • Quick Ratio: 9.01%
  • Average Volume: 694,529 shs.
  • Beta: 2.15
  • Short Ratio: 8.8

Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) announced its earnings results on Wednesday, May, 3rd. The company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.76) by $0.08. The business had revenue of $6.83 million for the quarter, compared to analyst estimates of $1.51 million. bluebird bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

16 brokers have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $37.00 to $135.00. On average, they expect bluebird bio's share price to reach $87.54 in the next twelve months. View Analyst Ratings for bluebird bio.

What are analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (5/8/2017)
  • 2. Maxim Group analysts commented, "bluebird reported 1Q17 with revenue of $6.8M (collaboration revenue) and a net loss of $68.7M." (5/5/2017)
  • 3. BTIG Research analysts commented, "Forecasts and Increased Conviction in Corp Strategy We have updated our outlook for bluebird bio (BLUE) and are raising our Price Target to $112 from $83 previously. Key points to our update include, 1) a positive outlook for the bb2121 update at ASCO, 2) favorable comps for LentiGlobin pricing, and 3) higher conviction in overall corporate strategy. We maintain our Buy recommendation.   Positive Risk Skew for bb2121 Dataset at ASCO: We anticipate that investors are looking for a continuation of responses within the 15 x 10^7 dose cohort along with sCR’s within the higher dose cohort (45×10^7), as there will be +3mos follow-up available for a number of patients (actual number not disclosed). SAEs such as CRS and Neurotox will be a focus, although we think that the dosing will be able to continue to push higher given the limited toxicity recorded to date. Our model now includes specific estimates for bb2121 reaching ~$287m of sales by 2021, under the assumption of a fast-track approval process for 4 th line BCMA+ Multiple Myeloma." (5/1/2017)
  • 4. BMO Capital Markets analysts commented, "We believe investors' focus will remain on continued progress of bluebird's pipeline where we look for multiple data readouts in 2017. For bb2121 we believe the focus will remain on safety, which we see as key point of differentiation versus other BCMA-focused CAR-T programs. For LentiGlobin we look for confirmation that Process 2 leads to better outcomes in SCD (data at ASH, December 9-12) and in ??0/??0 TDT. We have updated our model for 4Q results and reiterate our Market Perform rating and $83 price target." (2/23/2017)

Who are some of bluebird bio's key competitors?

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.96%), Baillie Gifford & Co. (12.71%), Vanguard Group Inc. (7.85%), BlackRock Inc. (7.77%), State Street Corp (3.93%) and OppenheimerFunds Inc. (2.37%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mitchell H Finer, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Wells Fargo & Company MN, Emerald Advisers Inc. PA, JPMorgan Chase & Co., Emerald Mutual Fund Advisers Trust, Bank of America Corp DE, Columbus Circle Investors and Morgan Stanley. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., State Street Corp, Baillie Gifford & Co., Pictet Asset Management Ltd. and FMR LLC. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of bluebird bio stock cost?

One share of bluebird bio stock can currently be purchased for approximately $79.80.

Analyst Ratings

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $87.54 (9.70% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
5/8/2017Morgan StanleyBoost Price TargetEqual Weight$87.00 -> $91.00MediumView Rating Details
5/1/2017BTIG ResearchReiterated RatingBuyMediumView Rating Details
3/24/2017Jefferies Group LLCReiterated RatingBuy$88.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
2/23/2017BMO Capital MarketsReiterated RatingMarket Perform$83.00N/AView Rating Details
12/10/2016Cantor FitzgeraldReiterated RatingSellN/AView Rating Details
12/7/2016JPMorgan Chase & Co.Reiterated RatingBuy$120.00N/AView Rating Details
12/4/2016Bank of America CorpReiterated RatingNeutral$68.00N/AView Rating Details
12/1/2016Leerink SwannBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$95.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
11/24/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
10/17/2016Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/15/2016Goldman Sachs Group IncReiterated RatingBuy$135.00N/AView Rating Details
10/14/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
5/5/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
11/5/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$162.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for bluebird bio (NASDAQ:BLUE)
Earnings by Quarter for bluebird bio (NASDAQ:BLUE)
Earnings History by Quarter for bluebird bio (NASDAQ:BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for bluebird bio (NASDAQ:BLUE)
2017 EPS Consensus Estimate: ($7.34)
2018 EPS Consensus Estimate: ($7.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.88)($1.79)($1.83)
Q2 20175($1.89)($1.71)($1.78)
Q3 20175($1.94)($1.73)($1.83)
Q4 20175($2.03)($1.78)($1.89)
Q1 20181($1.78)($1.78)($1.78)
Q2 20181($1.81)($1.81)($1.81)
Q3 20181($1.84)($1.84)($1.84)
Q4 20181($1.88)($1.88)($1.88)
(Data provided by Zacks Investment Research)


Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)
Insider Ownership Percentage: 3.50%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.00View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.00View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.00View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.00View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.00View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.59View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.10View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.78View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
DateHeadline logobluebird bio Announces Collaboration with Duke University's Robert J. Margolis, MD, Center for Health Policy on ... - Business Wire (press release) - May 23 at 4:01 PM logobluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy - May 23 at 12:26 PM logobluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 23, 2017 - May 23 at 12:26 PM logoETFs with exposure to bluebird bio, Inc. : May 22, 2017 - May 22 at 3:55 PM logobluebird bio (BLUE) to Present New Data from LentiGlobin Clinical Studies at EHA - - May 18 at 11:40 AM logobluebird bio to Present Updated Clinical Results from Novel Anti ... - Business Wire (press release) - May 18 at 11:40 AM logobluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting - May 18 at 11:40 AM logobluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting - May 17 at 9:01 PM logobluebird bio Inc (BLUE) to Post FY2017 Earnings of ($6.78) Per Share, Cantor Fitzgerald Forecasts - May 15 at 8:50 AM logobluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 12, 2017 - May 12 at 4:30 PM logobluebird bio Inc (BLUE) Expected to Earn Q2 2017 Earnings of ($1.77) Per Share - May 12 at 10:40 AM logoResearch Reports Coverage on Healthcare Stocks -- Radius Health, bluebird bio, Universal Health Services, and LifePoint Health - May 11 at 9:23 AM logobluebird bio Inc (BLUE) Given Consensus Recommendation of "Buy" by Brokerages - May 9 at 9:06 AM logobluebird bio Inc (BLUE) Upgraded by Zacks Investment Research to "Hold" - May 8 at 11:26 PM logoETFs with exposure to bluebird bio, Inc. : May 8, 2017 - May 8 at 8:53 PM logoMorgan Stanley Reaffirms Equal Weight Rating for bluebird bio Inc (BLUE) - May 8 at 1:22 PM logoQ2 2017 EPS Estimates for bluebird bio Inc (BLUE) Increased by Analyst - May 8 at 8:21 AM logoSunTrust Banks Comments on bluebird bio Inc's Q2 2017 Earnings (BLUE) - May 8 at 8:21 AM logobluebird bio's (BLUE) "Hold" Rating Reiterated at Maxim Group - May 6 at 2:40 PM logobluebird bio Updates, Investors Wait - Motley Fool - May 5 at 8:59 PM logoAnalysts Issue Forecasts for bluebird bio Inc's Q1 2018 Earnings (BLUE) - May 5 at 5:24 PM logobluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress - Business Wire (press release) - May 5 at 3:58 PM logobluebird bio, Inc. :BLUE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 - May 5 at 3:58 PM logobluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies - Business Wire (press release) - May 4 at 9:06 PM logobluebird bio Inc (BLUE) Announces Earnings Results, Beats Expectations By $0.08 EPS - May 4 at 4:43 PM logobluebird bio (BLUE) Earning Favorable Media Coverage, Analysis Shows - May 4 at 4:32 PM logoBRIEF-Bluebird bio Q1 total revenue $6.8 million - May 4 at 4:03 PM logobluebird bio (BLUE) , GlaxoSmithKline (GSK) Enters Lentiviral Vector Patent License Agreement - - May 3 at 9:01 PM logobluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress - Yahoo Finance - May 3 at 9:01 PM logobluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress - May 3 at 9:01 PM logoBluebird reports 1Q loss - May 3 at 9:01 PM logobluebird bio (BLUE) , GlaxoSmithKline (GSK) Enters Lentiviral Vector Patent License Agreement - May 3 at 10:34 AM logoBRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies - May 2 at 5:53 PM logobluebird bio Inc (BLUE) Director Daniel Lynch Sells 1,000 Shares - May 1 at 10:18 PM logobluebird bio (BLUE) Earning Favorable Press Coverage, Report Shows - May 1 at 2:38 PM logobluebird bio Inc (BLUE) Rating Reiterated by BTIG Research - May 1 at 9:28 AM logobluebird bio Inc (BLUE) Set to Announce Quarterly Earnings on Tuesday - April 30 at 7:33 AM logo Brokerages Anticipate bluebird bio Inc (BLUE) Will Post Quarterly Sales of $1.51 Million - April 29 at 10:17 AM logoBetter Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio - Motley Fool - April 28 at 2:22 AM logobluebird bio Inc (BLUE) Director Daniel Lynch Sells 2,000 Shares - April 27 at 9:44 PM logobluebird bio to Present at Upcoming Investor Conferences - Yahoo Finance - April 27 at 4:19 PM logo3 Things You Didn't Know About bluebird bio, Inc. - Motley Fool - April 27 at 4:19 PM logoBetter Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio - April 27 at 4:19 PM logoZacks: Analysts Anticipate bluebird bio Inc (BLUE) to Announce -$1.72 Earnings Per Share - April 27 at 8:48 AM logobluebird bio to Present at Upcoming Investor Conferences - April 26 at 6:09 PM logo3 Things You Didn't Know About bluebird bio, Inc. - April 26 at 1:09 PM logobluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : April 26, 2017 - April 26 at 1:09 PM logobluebird bio (BLUE) Earning Positive Media Coverage, AlphaOne Reports - April 26 at 12:50 PM logobluebird bio Inc (BLUE) Downgraded by Zacks Investment Research - April 25 at 8:54 PM logobluebird bio (BLUE) Given Daily Media Sentiment Rating of 0.12 - April 23 at 1:23 PM



bluebird bio (BLUE) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff